Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986179

Next Previous
Search
Drug Profile

BMS 986179

Alternative Names: BMS-986179

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 12 Oct 2021 Bristol-Myers Squibb completes a phase I/IIa trial for in Solid tumours (Late-stage disease, Combination therapy) in Australia, Canada, France, Germany, Italy, Netherlands(IV) (NCT02754141)
  • 25 Feb 2021 BMS 986179 is still in phase I/II development for Solid tumours
  • 31 Oct 2018 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease) in USA, Australia, Canada, France, Italy, Germany, Netherlands (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top